



Clinical Trial

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study



Michel Ducreux ^{a,*}, Lone Nørgård Petersen ^b, Leopold Öhler ^c,
 Francesca Bergamo ^d, Jean-Philippe Metges ^e, Jan Willem de Groot ^f,
 Jaw-Yuan Wang ^g, Beatriz García Paredes ^h, Emmanuelle Dochy ⁱ,
 Sabine Fiala-Buskies ^j, Andrés Cervantes ^k, Juan Manuel O'Connor ^l,
 Alfredo Falcone ^m on behalf of the CORRELATE Investigators ⁿ

^a Gastrointestinal Oncology Unit, Gustave Roussy Cancer Campus Grand Paris, Université Paris-Saclay, Villejuif, France

^b Department of Oncology, Rigshospitalet, Copenhagen, Denmark

^c Internal Medicine I, Department of Oncology, St. Josef Krankenhaus, Vienna, Austria

^d Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

^e Service d'Oncologie et de Radiothérapie, CHU de Brest – Hôpital Morvan, ARPEGO Network, Brest, France

^f Isala Oncology Center, Zwolle, Netherlands

^g Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan

^h Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain

ⁱ Global Medical Affairs Oncology, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA

^j Medical Affairs Statistics and Integrated Analysis, Bayer AG, Wuppertal, Germany

^k Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain

^l Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, Argentina

^m Department of Medical Oncology, University of Pisa, Pisa, Italy

Received 26 July 2019; received in revised form 10 September 2019; accepted 12 September 2019

Available online 4 November 2019

KEYWORDS

Regorafenib;
 Survival analysis;
 Observational study;
 Adverse effects

Abstract *Background:* Regorafenib prolonged overall survival (OS) versus placebo in patients with treatment-refractory metastatic colorectal cancer (mCRC) in phase III trials. We conducted an observational study of regorafenib for patients with mCRC in real-world clinical practice.

Methods: The international, prospective, CORRELATE study recruited patients with mCRC previously treated with approved therapies, for whom the decision to treat with regorafenib

* Corresponding author. Gustave Roussy Cancer Campus Grand Paris, Université Paris-Saclay, Institut Gustave Roussy, 114 rue Edouard-Vaillant, 94805 Villejuif, France.

E-mail address: Michel.Ducreux@gustaveroussy.fr (M. Ducreux).

ⁿ A list of the CORRELATE Investigators can be found in [Appendix Table 3](#).

<https://doi.org/10.1016/j.ejca.2019.09.015>

0959-8049/© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

was made by the treating physician according to the local health authority approved label. The primary objective was safety, assessed by treatment-emergent adverse events (TEAEs; National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03).

Results: A total of 1037 patients were treated. The median age was 65 years (range: 24–93); 87% of patients had Eastern Cooperative Oncology Group performance status 0–1, 56% of patients had *KRAS*, 7% had *NRAS* and 4% had *BRAF* mutations. The initial regorafenib dose was 160 mg/day in 57% of patients. The most common grade III or IV drug-related TEAEs were fatigue (9%), hand–foot skin reaction (7%) and hypertension (6%). Drug-related grade V (fatal) TEAEs occurred in 1% of patients. Dose reductions for drug-related TEAEs occurred in 24% of patients. Median OS was 7.7 months (95% confidence interval [CI]: 7.2–8.3), and median progression-free survival (PFS) was 2.9 months (95% CI: 2.8–3.0).

Conclusions: In this real-world, observational study of patients with mCRC, the regorafenib toxicity profile was similar to that reported in phase III trials. The starting dose for almost half of patients was less than the approved 160-mg dose, and the median OS and PFS were in the range observed in phase III trials.

Trial registration: NCT02042144.

© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Regorafenib is a multikinase inhibitor, first approved in 2012 for patients with metastatic colorectal cancer (mCRC) and disease progression after standard therapies [1–4]. Subsequently, it was approved for patients with advanced gastrointestinal stromal tumours and patients with unresectable hepatocellular carcinoma [3–6]. The approved starting dose of regorafenib is 160 mg orally once daily for the first 3 weeks of each 4-week cycle [3,4].

Regorafenib was evaluated in treatment-refractory mCRC in three large, international trials [2,7,8]. In the randomised, phase III CORRECT trial, regorafenib improved overall survival (OS) versus placebo, with a hazard ratio (HR) of 0.77 (95% confidence interval [CI]: 0.64–0.94; one-sided $P = 0.0052$) and a median OS of 6.4 versus 5.0 months [2]. Progression-free survival (PFS) was also significantly improved (HR: 0.49; 95% CI: 0.42–0.58; one-sided $P < 0.0001$); median PFS was 1.9 versus 1.7 months. The most common grade III or higher drug-related treatment-emergent adverse events (TEAEs) in the CORRECT trial were hand–foot skin reaction (HFSR), fatigue, diarrhoea, hypertension and rash or desquamation [2]. The randomised, phase III CONCUR trial confirmed the efficacy and safety of regorafenib in Asian patients with mCRC [7]. The single-arm, phase IIIb CONSIGN trial, carried out in nearly 3000 patients with mCRC, showed that the safety profile and median PFS were consistent with the results of the CORRECT and CONCUR trials [2,7,8].

The selected patient populations and regulated protocols characterising phase III trials may not reflect the real-world contexts in which patients are treated [9,10]. Data from observational studies can help address this gap, complementing the findings of interventional trials

[10]. We report the results of CORRELATE, a prospective, observational study designed to characterise the safety and effectiveness of regorafenib in an unselected, real-world population of patients with mCRC treated in routine clinical practice settings.

2. Patients and methods

2.1. Study design

CORRELATE was a prospective, observational, cohort study conducted in 126 centres in Europe, Asia and Latin America (NCT02042144). The study population comprised patients with mCRC who were previously treated with, or who were not considered candidates for, other approved therapies and for whom a decision was made by the treating physician to treat with regorafenib according to the local health authority approved label. The observation period for each patient was the time from treatment initiation until death, withdrawal of consent, loss to follow-up or the end of the study. The frequency of tumour evaluations was not defined; assessments were conducted according to the treating physician's routine practice. Patients participating in any investigational program with interventions outside routine practice were excluded. All patients provided signed informed consent.

The primary objective was to characterise the safety of regorafenib for mCRC in real-world practice, assessed by TEAEs during treatment through 30 days after treatment, using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03. The secondary objective was to assess effectiveness, as measured by OS—the time from treatment start until death; PFS—the time from treatment start until radiological or clinical progression

or death; and the disease control rate (DCR)—the percentage of patients with complete response, partial response or stable disease lasting at least 6 weeks.

For each patient, the treating physician documented an initial visit, when regorafenib was started, follow-up visits and a final visit. There was no fixed visit schedule; visits followed local routine clinical practice. The physician collected data (demographic and baseline disease characteristics) from medical records or by interview at the initial visit. Treatment-related data, including adverse events and tumour status, were collected during follow-up visits. After treatment discontinuation, physicians were encouraged to contact patients every 2 months to assess survival. They were encouraged to make at least three efforts, 1 month apart, via visits, telephone calls, emails or contacting other physicians. Information on survival status obtained from public records could also be used. A final visit was documented at death, withdrawal of consent, loss to follow-up or the end of the study.

2.2. Statistical analysis

Using a sample size of 1000 patients, a previously unreported adverse event with a true incidence of 1 per 1000 would have a 63% probability of being observed. To avoid potential selection bias and increase representativeness, patients were selected only based on inclusion and exclusion criteria, and investigators were encouraged to enrol consecutive patients.

Statistical analyses were exploratory and descriptive. Categorical variables were analysed by frequency tables, and continuous variables were analysed by sample statistics. All patients who received at least one dose of regorafenib were included in the safety and effectiveness analyses. OS and PFS were estimated using the Kaplan-Meier method. Patients without calculable OS were censored at day 1, and patients with an unknown date of death were censored at the last date they were known to be alive. Patients without calculable PFS were censored at day 1, and patients with an unknown date of progression were censored at the last date they were known not to have progressed or at day 1 if no tumour assessment existed. An interim analysis was performed after 500 patients had been observed for at least 3 months [11]. The final analysis was performed after all patients were enrolled and followed up until 6 months after regorafenib discontinuation or until death, withdrawal of consent or loss to follow-up, whichever came first.

Exploratory analyses of OS and PFS were performed in subgroups defined by primary tumour location: left-sided (splenic flexure, descending colon, sigmoid/rectosigmoid colon or rectum) versus right-sided (caecum, appendix, ascending colon or hepatic flexure). Patients with primary tumours in the transverse colon and patients with both left-sided and right-sided primary

tumours were excluded. An exploratory analysis of OS was performed in subgroups of patients with a resected versus unresected primary tumour.

3. Results

Between 8 April 2014 and 18 January 2017, 1048 patients were enrolled. Of those, 11 patients were not treated and were excluded from the analysis. A total of 1037 patients were treated between 9 April 2014 and 21 July 2017, and all patients were analysed for safety and effectiveness (Fig. 1). The final analysis cut-off date was 15 December 2017.

Patients were enrolled from Europe ($n = 883$), Asia ($n = 133$) and Latin America ($n = 21$), including 242 from France, 193 from Italy, 143 from Spain, 136 from Austria and 128 from Taiwan. Approximately half the patients were 65 years or older (Table 1). The primary tumour site was the colon in 70% ($n = 721$) of patients, the rectum in 28% ($n = 294$) and the colon and rectum in 2% ($n = 21$); the primary tumour site was missing for one patient. Most patients (87%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Thirty-nine percent of patients had received at least four prior systemic anti-cancer therapies.

The median duration of treatment was 2.5 months (range: 0.03–29.5; Table 2). Fifty-seven percent of patients ($n = 591$) started regorafenib at the approved daily dose of 160 mg, 30% of patients ($n = 315$) started at 120 mg daily and 12% of patients ($n = 127$) started at 80 mg daily. Patients starting at 80 mg tended to be older, were more likely to be Asian and had a worse ECOG performance status than patients starting at 120 mg or 160 mg (Appendix Table 1). In approximately 60% of patients, the initial dose was the same as the last dose (Table 2). Forty-eight percent of patients had at least one treatment interruption, and 40% had at least one dose reduction (Table 2). The median time to the first dose modification was 21 days. Most dose modifications (66%; 1187/1809 events) were due to adverse events.

3.1. Safety

Most patients (95%) had at least one TEAE, and 80% had a TEAE judged regorafenib-related (Table 3). Regorafenib-related grade III or IV TEAEs were reported in 35% of patients. Grade V (fatal) TEAEs were reported in 17% of patients and were judged regorafenib-related in 1% ($n = 10$; Appendix Table 2). The most common regorafenib-related grade III or IV TEAEs were fatigue (9%), HFSR (7%) and hypertension (6%) (Table 3).

Approximately one-quarter of patients (24%; $n = 251$) had a dose reduction due to a regorafenib-




Fig. 1. Patients enrolled and treated. AE, adverse effect.

related TEAE and 31% ($n = 319$) had a treatment interruption due to a regorafenib-related TEAE (Appendix Table 2). Treatment was permanently discontinued because of a regorafenib-related TEAE in 16% of patients ($n = 163$).

3.2. Effectiveness

The median OS was 7.7 months (95% CI: 7.2–8.3; interquartile range [IQR]: 3.9–15.2; Fig. 2A). The 3-month, 6-month and 1-year estimates for OS were 83%, 60% and 34%, respectively. The median PFS was 2.9 months (95% CI: 2.8–3.0; IQR: 1.9–5.0) (Fig. 2B).

In patients with left-sided primary tumours ($n = 761$), the median OS was 7.5 months (95% CI: 6.8–8.1; IQR: 4.0–15.1) and the median PFS was 2.9 months (95% CI: 2.8–3.1; IQR: 1.9–5.1) (Appendix Fig. 1A and B). In patients with right-sided primary tumours ($n = 206$), the median OS was 8.2 months (95% CI: 6.6–9.4; IQR: 3.6–15.0) and the median PFS was 2.8 months (95% CI: 2.6–3.3; IQR: 1.8–5.0). Patients whose primary tumour was resected ($n = 806$) had a median OS of 8.2 months (95% CI: 7.6–8.8), compared with 5.8 months (95% CI: 4.7–7.1) in patients with unresected primary tumours ($n = 229$).

In this observational study, in which intervals for tumour assessments were not defined, a total of 758

patients (73%) had at least one tumour assessment (radiological or clinical) and 279 (27%) had no tumour assessment. Of the 758 patients with at least one assessment, 68% of patients (513/758) had one assessment and 21% of patients (159/758) had two assessments. Based on patients with at least one assessment, no patient (0/758) had a complete response, 4% of patients (31/758) had a partial response and 22% of patients (164/758) had stable disease lasting at least 6 weeks. Six patients had stable disease documented earlier than 6 weeks after treatment start. The DCR was 26% (195/758).

4. Discussion

This prospective, observational study of more than 1000 patients characterised the safety and effectiveness of regorafenib in mCRC in real-life practice settings. The safety profile of regorafenib was consistent with reports from the phase III trials, with lower rates of some TEAEs, possibly because of more effective management of adverse events [2,7,8]. Although many patients initiated regorafenib at doses lower than the approved label dose, the median OS and PFS were in the range of what was reported in prior trials [2,7,8].

The patient population in CORRELATE was typical of patients with mCRC and generally similar to

Table 1
Demographics and baseline characteristics.

	Regorafenib (N = 1037)
Age (years), median (range)	65 (24–93)
Age ≥65 years, n (%)	544 (52)
Male, n (%)	629 (61)
Race, n (%) ^a	
White	643 (62)
Asian	133 (13)
Black	2 (<1)
American Indian or Alaska native	2 (<1)
Not reported	259 (25)
ECOG PS, n (%)	
0	426 (41)
1	477 (46)
2–4	66 (6)
Missing	68 (7)
Body mass index (kg/m ²), median (IQR) ^b	24 (22–28)
Body weight (kg), median (IQR) ^c	70 (59–80)
Primary tumour site, n (%) ^a	
Appendix	9 (1)
Caecum	75 (7)
Ascending colon	127 (12)
Hepatic flexure	18 (2)
Transverse colon	63 (6)
Splenic flexure	17 (2)
Descending colon	112 (11)
Sigmoid colon	281 (27)
Rectosigmoid colon	85 (8)
Rectum	315 (30)
Missing	1 (<1)
Primary tumour classification by location, n (%) ^d	
Right-sided	206 (20)
Left-sided	761 (73)
Left- and right-sided	6 (1)
Not assessable	64 (6)
<i>KRAS</i> mutation status, n (%)	
Wild-type	387 (37)
Mutant	581 (56)
Unknown	69 (7)
<i>NRAS</i> mutation status, n (%)	
Wild-type	495 (48)
Mutant	73 (7)
Unknown	469 (45)
<i>BRAF</i> mutation status, n (%)	
Wild-type	518 (50)
Mutant	46 (4)
Unknown	473 (46)
Main metastatic sites at study entry, n (%) ^e	
Liver	747 (72)
Lung	592 (57)
Lymph node	169 (16)
Peritoneum	134 (13)
Bone ^f	118 (11)
Status of primary tumour at treatment start, n (%)	
Resected	806 (78)
Unresected	229 (22)
Missing	2 (<1)
Time from diagnosis of metastatic disease at study start, months ^g	
Median (range)	26 (<1–169)
<18 months, n (%)	314 (30)
≥18 months, n (%)	714 (69)
Prior systemic anti-cancer therapy, n (%)	
Any	1025 (99)
Anti-VEGF	896 (86)
Anti-EGFR	408 (39)

Table 1 (continued)

	Regorafenib (N = 1037)
Number of prior systemic anti-cancer therapies	
Median (IQR)	3 (2–4)
0, n (%)	12 (1)
1–2, n (%)	316 (30)
3, n (%)	307 (30)
≥4, n (%)	402 (39)

ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; IQR, interquartile range; VEGF, vascular endothelial growth factor.

^a Multiple answers possible.

^b n = 780.

^c n = 833.

^d Left-sided primary tumours were those in the splenic flexure, descending colon, sigmoid/rectosigmoid colon or rectum; right-sided primary tumours were those in the caecum, appendix, ascending colon or hepatic flexure; patients with primary tumours in the transverse colon were not assessable.

^e Patients may have had >1 metastatic site.

^f Includes spine.

^g n = 1028.

populations in phase III trials in mCRC. The median age was 65 years, slightly older than that in the CORRECT (61 years, regorafenib arm) and CONSIGN (62 years) trials and considerably older than the median age in the CONCUR (58 years, regorafenib arm) and IMblaze370 (58 years) trials [2,7,8,12]. Fifty-two percent of patients in CORRELATE were 65 years or older, compared with 40% in CONSIGN [8]. Most patients in CORRELATE (86%) had received prior anti-VEGF treatment, similar to patients in other studies [2,8,13], and 39% of patients had received at least four prior systemic anti-cancer therapies. Approximately half of patients had *KRAS*-mutant tumours, similar to the proportions in other studies [2,13], and *BRAF* mutations were found in 46 patients (4%), similar to the proportion in CORRECT (4%, regorafenib arm) [2]. Thirty percent of patients had been diagnosed with metastatic disease for less than 18 months, a higher proportion than those in the CORRECT (18%, regorafenib arm), CONSIGN (18%) and RECOURSE (21%, TAS-102 arm) trials, and a lower proportion than that in the CONCUR trial (39%, regorafenib arm) [2,7,8,13]. Unlike many phase III trials in mCRC, CORRELATE enrolled patients with an ECOG performance status of 2–4, who constituted 6% of the study population [2,7,13].

The incidence and severity of TEAEs in CORRELATE were generally consistent with the known safety profile of regorafenib. The most frequently reported regorafenib-related TEAEs were fatigue, HFSR, diarrhoea, oral mucositis and hypertension, which were also among the most frequently reported regorafenib-related TEAEs in the CORRECT, CONCUR and CONSIGN trials [2,7,8]. No new safety signals were observed. The incidence rates of some regorafenib-related TEAEs were lower in CORRELATE than in CORRECT, including HFSR (26% vs 47%), diarrhoea (19% vs 34%), anorexia

Table 2
Treatment duration and modifications by initial daily dose.

	160 mg (n = 591)	120 mg (n = 315)	80 mg (n = 127)	All patients ^a (N = 1037)
Duration of treatment, months				
Median (range)	2.6 (0.03–29.5)	2.4 (0.03–20.6)	2.3 (0.16–15.4)	2.5 (0.03–29.5)
Mean (SD)	3.2 (2.9)	3.3 (3.3)	3.2 (3.0)	3.3 (3.0)
Any dose modification, n (%) ^b	386 (65)	200 (63)	89 (70)	678 (65)
Dose reduction	278 (47)	107 (34)	28 (22)	415 (40)
Dose interruption/delay	293 (50)	149 (47)	58 (46)	501 (48)
Re-escalation ^c	40 (7)	59 (19)	61 (48)	163 (16)
Escalation ^d	0	47 (15)	61 (48)	111 (11)
No treatment modification	205 (35)	115 (37)	38 (30)	359 (35)
Time (days) to first dose modification, median (range)	21 (1–403)	26 (1–242)	19 (3–133)	21 (1–403)
Last daily dose, n (%) ^e				
160 mg	326 (55)	35 (11)	10 (8)	373 (36)
120 mg	166 (28)	196 (62)	30 (24)	393 (38)
80 mg	94 (16)	79 (25)	82 (65)	255 (25)
40 mg	4 (1)	4 (1)	4 (3)	13 (1)

SD, standard deviation.

^a Four patients who initiated treatment at 40 mg daily are included in the analysis of all patients but are not shown separately.

^b Modifications include reductions, interruptions/delays, re-escalations and escalations.

^c Dose higher than the last non-zero dose.

^d Dose higher than initial dose.

^e Three patients are not shown: one in the 80-mg group whose last daily dose was 20 mg, and two (one in the 120-mg group; one in the 160-mg group) whose last daily dose was 100 mg.

(13% vs 30%) and hypertension (14% vs 28%) [2]. The lower rates could be due to better adverse event management, the proportion of patients starting treatment at doses lower than 160 mg or underreporting.

The starting dose of regorafenib for almost half the patients was less than the approved 160-mg daily dose. Physicians previously described starting regorafenib at doses less than 160 mg and increasing the dose as tolerated [14,15]. A recent randomised phase II trial (ReDOS) reported that weekly dose escalation from 80 mg to 160 mg during the first cycle allowed more patients to complete two cycles of treatment and initiate a third compared with starting at the approved 160-mg dose [16]. In CORRELATE, patients starting regorafenib at 80 mg daily tended to be older, were more likely to be Asian and had a worse performance status, a

lower body weight and a lower body mass index than those starting at 160 mg or 120 mg daily. The rates of dose reductions due to TEAEs and dose interruptions due to TEAEs in CORRELATE were lower than those in CORRECT, CONCUR and CONSIGN, likely due to many patients starting treatment at doses lower than 160 mg [2,7,8].

Despite the different dosing schedules reported in CORRELATE, regorafenib effectiveness was consistent with previous reports [2,7,8]. The results of ReDOS support this flexible dosing approach, showing that a dose-escalation schedule can be used in clinical practice [16]. Exploratory analyses of effectiveness in CORRELATE showed that OS and PFS were similar for patients with left- and right-sided tumours, suggesting that although tumour sidedness has been found to be

Table 3
Treatment-emergent adverse events and drug-related treatment-emergent adverse events.^a

n (%)	Regorafenib (N = 1037)					
	Treatment-emergent adverse events			Drug-related treatment-emergent adverse events		
	All-grade	Grade III	Grade IV	All-grade	Grade III	Grade IV
Any event	990 (95)	426 (41)	41 (4)	830 (80)	338 (33)	22 (2)
Fatigue	545 (53)	106 (10)	NA	425 (41)	89 (9)	NA
HFSR	281 (27)	77 (7)	NA	273 (26)	77 (7)	NA
Diarrhoea	261 (25)	38 (4)	2 (<1)	196 (19)	31 (3)	1 (<1)
Anorexia	228 (22)	22 (2)	0	137 (13)	16 (2)	0
Mucositis oral	185 (18)	23 (2)	0	159 (15)	21 (2)	0
Hypertension	174 (17)	78 (8)	1 (<1)	144 (14)	65 (6)	1 (<1)
Abdominal pain	168 (16)	36 (3)	NA	29 (3)	4 (<1)	NA
Nausea	130 (13)	6 (1)	NA	74 (7)	3 (<1)	NA
Fever	126 (12)	2 (<1)	0	26 (3)	2 (<1)	0

HFSR, hand–foot skin reaction; NA, not applicable.

National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03.

^a Events listed are treatment-emergent adverse events occurring in at least 10% of patients.




Fig. 2. Kaplan-Meier curves of overall survival (A) and progression-free survival (B). CI, confidence interval; IQR, interquartile range; PFS, progression-free survival; OS, overall survival.

prognostic, and even predictive, in the first-line setting [17,18], this effect may not be observed in later lines.

A limitation of this observational study is the lack of defined intervals for patient visits and tumour evaluations. This could have impacted the results, for example, leading to a longer documented PFS or a lower documented DCR than would have been observed with more frequent tumour evaluations, or to underreporting of adverse events. We found that many patients in CORRELATE had only one tumour assessment and that the observed DCR was lower than that reported in prior studies [2,7].

5. Conclusion

The safety profile of regorafenib in patients with mCRC in real-world practice settings is consistent with the safety profile demonstrated in phase III trials. Rates of some common regorafenib-related TEAEs were lower in CORRELATE than previously reported, possibly due to underreporting or proactive management of adverse events, including starting patients on doses lower than the approved 160-mg/day dose. Despite the flexible dosing observed in CORRELATE, the effectiveness of regorafenib was similar to reports from the phase III trials.

Funding

This study was sponsored by Bayer HealthCare AG. Bayer worked with the principal investigator (M.D.) and the study steering committee to design the study. Data collection and interpretation and preparation of this manuscript were performed by the authors and Bayer. All authors reviewed the manuscript and approved its submission for publication.

Acknowledgements

The authors thank the patients in the CORRELATE study, their families and the CORRELATE investigators and participating study centres. A list of the CORRELATE investigators can be found in the Appendix (Appendix Table 3). This study was sponsored by Bayer HealthCare AG. Editorial assistance in the preparation of this manuscript was provided by Jennifer Tobin of OPEN Health Medical Communications (Choice), with financial support from Bayer.

Conflict of interest statement

M.D. reports receiving personal fees and non-financial support, including travel for a congress, from Bayer for the present work; personal fees from Servier, MSD, Novartis, Ipsen, Lilly and Shire; grants and personal fees, including travel for a congress, from Roche;

grants and personal fees from Merck Serono; personal fees, including travel for a congress, from Amgen and reports that an immediate family member is the head of the Oncology Business Unit of the Sandoz affiliate in France. J.-P.M. reports receiving honoraria from Lilly, Merck Serono, Novartis and Sanofi. J.W.D.G. reports receiving personal fees from Bristol-Myers Squibb, Roche, Pierre Fabre, Servier, MSD and Novartis. E.D. reports employment by Bayer and stock ownership in Sanofi. S.F.-B. reports employment by and stock ownership in Bayer. A.C. reports receiving personal fees and research funding paid to his institution from Bayer for the present work; grants, personal fees and research funding paid to his institution from BeiGene, Merck Serono and Roche; personal fees and research funding paid to his institution from Servier, Lilly, Novartis, Takeda and Astellas; personal fees from Amgen and Foundation Medicine and research funding paid to his institution from FibroGen, amcure, Sierra Oncology, AstraZeneca, MedImmune, Bristol-Myers Squibb, MSD and Genentech and holding the positions of General and Scientific Director of the Biomedical Research Institute INCLIVA and Chair of Education at the European Society for Medical Oncology. A.F. reports receiving grants, personal fees and non-financial support from Amgen, Bayer, Merck, Lilly, Sanofi, Roche, Bristol-Myers Squibb, MSD and Servier. L.N.P., L.O., F.B., J.-Y.W., B.G.P. and J.M.O. declare no conflicts of interest.

Appendix A Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ejca.2019.09.015>.

References

- [1] Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, et al. Regorafenib (BAY 73-4506): a new oral multi-kinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. *Int J Cancer* 2011;129(1):245–55.
- [2] Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381(9863):303–12.
- [3] STIVARGA (regorafenib) tablets Prescribing Information. Whippany, NJ, USA: Bayer HealthCare Pharmaceuticals Inc.; 2018.
- [4] STIVARGA (regorafenib) Summary of product characteristics. Leverkusen, Germany: Bayer AG; 2018.
- [5] Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381(9863):295–302.
- [6] Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who

- progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017; 389(10064):56–66.
- [7] Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2015;16(6):619–29.
- [8] Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, et al. Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label phase IIIb CONSIGN study. *The Oncologist* 2019;24(2):185–92.
- [9] Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence - what is it and what can it tell us? *N Engl J Med* 2016;375(23):2293–7.
- [10] Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. *Br J Canc* 2014;110(3):551–5.
- [11] Ducreux M, Öhler L, Scheithauer W, Metges J-P, Dourthe L-M, De Groot JW, et al. Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: an interim analysis (IA) from the prospective, observational CORRELATE study. *J Clin Oncol* 2017;35(4S). Abstract 700.
- [12] Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncol* 2019;20(6):849–61.
- [13] Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med* 2015; 372(20):1909–19.
- [14] Grothey A. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations. *Clin Adv Hematol Oncol* 2015;13(8):514–7.
- [15] Tabchi S, Ghosn M. Regorafenib: start low and go slow. *Target Oncol* 2015;10(3):445–7.
- [16] Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. *Lancet Oncol* 2019;20(8): 1070–82.
- [17] Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil BH, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). *J Clin Oncol* 2016;34(15S). Abstract 3504.
- [18] Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. *Ann Oncol* 2017;28(8):1713–29.